Aura Biosciences (NASDAQ:AURA) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Aura Biosciences (NASDAQ:AURA) from a sell rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Other analysts have also issued reports about the stock. Citigroup reiterated a “market outperform” rating on shares of Aura Biosciences in a research note on Tuesday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Finally, HC Wainwright lowered their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Aura Biosciences Price Performance

Shares of AURA stock remained flat at $7.11 on Friday. The company had a trading volume of 610,304 shares, compared to its average volume of 811,384. The firm has a market capitalization of $739.94 million, a price-to-earnings ratio of -4.34 and a beta of 0.41. Aura Biosciences has a 52-week low of $4.73 and a 52-week high of $9.53. The firm has a 50-day moving average of $6.54 and a 200 day moving average of $6.77.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Equities analysts forecast that Aura Biosciences will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC raised its position in Aura Biosciences by 29.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,807,300 shares of the company’s stock valued at $23,910,000 after purchasing an additional 856,270 shares in the last quarter. 49 Wealth Management LLC purchased a new position in shares of Aura Biosciences in the 3rd quarter valued at about $111,000. HighTower Advisors LLC purchased a new position in shares of Aura Biosciences in the 3rd quarter valued at about $110,000. Russell Investments Group Ltd. grew its position in shares of Aura Biosciences by 203.6% during the third quarter. Russell Investments Group Ltd. now owns 54,618 shares of the company’s stock worth $343,000 after buying an additional 36,628 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Aura Biosciences by 74.0% during the third quarter. Parallel Advisors LLC now owns 9,857 shares of the company’s stock worth $62,000 after buying an additional 4,192 shares in the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.